Ionis Partner GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B
IONS has more than doubled off its 52-week low of $23.95.
Summary
Ionis Pharmaceuticals announced that its partner GSK reported positive topline results from two pivotal Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, meeting primary endpoints and demonstrating a statistically significant functional cure rate.
Key Events · Product Development and Regulatory · IONS
-
Positive Phase 3 Results
GSK, Ionis' partner, announced positive topline results from two pivotal Phase 3 studies (B-Well 1 and B-Well 2) for bepirovirsen in chronic hepatitis B (CHB).
-
Met Primary Endpoint
Both studies met their primary endpoint, demonstrating a statistically significant and clinically meaningful functional cure rate for bepirovirsen.
-
Significant Market Opportunity
Bepirovirsen targets CHB, a major global health challenge affecting over 250 million people, with potential to be the first finite, six-month therapeutic option.
-
Regulatory Designations
The drug has received Fast Track designation from the US FDA, Breakthrough Therapy designation in China, and SENKU designation in Japan, highlighting its innovation and unmet need.
Analysis · IONS · Life Sciences
This filing is highly significant as it announces positive Phase 3 results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, a disease affecting over 250 million people globally with limited current cure options. The successful trial outcomes, coupled with existing Fast Track and Breakthrough Therapy designations, significantly de-risk the program and pave the way for global regulatory submissions. For Ionis, this represents a substantial future revenue stream through milestone payments and tiered royalties, reinforcing the value of its antisense oligonucleotide technology and its collaborative development model. This positive readout also sets a strong precedent as the first of several anticipated Phase 3 results for Ionis this year.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $83.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $23.95 to $86.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.